Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies approved for the treatment of numerous cancer types. Toxicities induced by ICIs may affect any organ system and manifest as endocrinopathy. The main side effects related to treatment are immune-related adverse events (irAEs), especially t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2023-01-01
|
| Series: | Endocrine Oncology |
| Subjects: | |
| Online Access: | https://eo.bioscientifica.com/view/journals/eo/2/1/EO-22-0047.xml |
| _version_ | 1797955466518593536 |
|---|---|
| author | Alexander Kreze Matěj Homer Tereza Barešová Kristina Klemperová |
| author_facet | Alexander Kreze Matěj Homer Tereza Barešová Kristina Klemperová |
| author_sort | Alexander Kreze |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) are monoclonal antibodies approved for the treatment of numerous cancer types. Toxicities induced by ICIs may affect any organ system and manifest as endocrinopathy. The main side effects related to treatment are immune-related adverse events (irAEs), especially thyroid dysfunction and hypophysitis. Rare endocrine irAEs are diabetes insipidus, hypoparathyroidism, thyrotoxic crisis and hypogonadism. We report a case of hypoparathyroidism induced by ICI treatment with durvalumab, which has not previously been described. |
| first_indexed | 2024-04-10T23:34:37Z |
| format | Article |
| id | doaj.art-10342f22fdd749bfb0449258804674a2 |
| institution | Directory Open Access Journal |
| issn | 2634-4793 |
| language | English |
| last_indexed | 2024-04-10T23:34:37Z |
| publishDate | 2023-01-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Oncology |
| spelling | doaj.art-10342f22fdd749bfb0449258804674a22023-01-12T00:49:52ZengBioscientificaEndocrine Oncology2634-47932023-01-0121K21K24https://doi.org/10.1530/EO-22-0047Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumabAlexander Kreze0Matěj Homer1Tereza Barešová2Kristina Klemperová3Endocrine Clinic of Internal Medicine Department, The Bulovka University Hospital, Praha, Czech Republic; Endocrine Clinic of Internal Medicine Department, The Bulovka University Hospital, Praha, Czech Republic Endocrine Clinic of Internal Medicine Department, The Bulovka University Hospital, Praha, Czech RepublicEndocrine Clinic of Internal Medicine Department, The Bulovka University Hospital, Praha, Czech RepublicDepartment of Biochemistry, The Bulovka University Hospital, Praha, Czech RepublicImmune checkpoint inhibitors (ICIs) are monoclonal antibodies approved for the treatment of numerous cancer types. Toxicities induced by ICIs may affect any organ system and manifest as endocrinopathy. The main side effects related to treatment are immune-related adverse events (irAEs), especially thyroid dysfunction and hypophysitis. Rare endocrine irAEs are diabetes insipidus, hypoparathyroidism, thyrotoxic crisis and hypogonadism. We report a case of hypoparathyroidism induced by ICI treatment with durvalumab, which has not previously been described.https://eo.bioscientifica.com/view/journals/eo/2/1/EO-22-0047.xmlimmune checkpoint inhibitorsdurvolumabimmune-related adverse effectshypoparathyroidism |
| spellingShingle | Alexander Kreze Matěj Homer Tereza Barešová Kristina Klemperová Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab Endocrine Oncology immune checkpoint inhibitors durvolumab immune-related adverse effects hypoparathyroidism |
| title | Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab |
| title_full | Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab |
| title_fullStr | Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab |
| title_full_unstemmed | Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab |
| title_short | Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab |
| title_sort | hypoparathyroidism an uncommon adverse effect of treatment with durvalumab |
| topic | immune checkpoint inhibitors durvolumab immune-related adverse effects hypoparathyroidism |
| url | https://eo.bioscientifica.com/view/journals/eo/2/1/EO-22-0047.xml |
| work_keys_str_mv | AT alexanderkreze hypoparathyroidismanuncommonadverseeffectoftreatmentwithdurvalumab AT matejhomer hypoparathyroidismanuncommonadverseeffectoftreatmentwithdurvalumab AT terezabaresova hypoparathyroidismanuncommonadverseeffectoftreatmentwithdurvalumab AT kristinaklemperova hypoparathyroidismanuncommonadverseeffectoftreatmentwithdurvalumab |